AU2016210988B2 - Embryo implantation - Google Patents

Embryo implantation Download PDF

Info

Publication number
AU2016210988B2
AU2016210988B2 AU2016210988A AU2016210988A AU2016210988B2 AU 2016210988 B2 AU2016210988 B2 AU 2016210988B2 AU 2016210988 A AU2016210988 A AU 2016210988A AU 2016210988 A AU2016210988 A AU 2016210988A AU 2016210988 B2 AU2016210988 B2 AU 2016210988B2
Authority
AU
Australia
Prior art keywords
vaginal
csf
female
vagina
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016210988A
Other languages
English (en)
Other versions
AU2016210988A1 (en
Inventor
David Andrew BROOKE
Nadia Gopichandran
Nicolas Michel Orsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ostara Biomedical Ltd
Original Assignee
Ostara Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ostara Biomedical Ltd filed Critical Ostara Biomedical Ltd
Publication of AU2016210988A1 publication Critical patent/AU2016210988A1/en
Application granted granted Critical
Publication of AU2016210988B2 publication Critical patent/AU2016210988B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/02—Instruments or methods for reproduction or fertilisation for artificial insemination
    • A61D19/022—Containers for animal semen, e.g. pouches or vials ; Methods or apparatus for treating or handling animal semen containers, e.g. filling or closing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AU2016210988A 2015-01-27 2016-01-27 Embryo implantation Ceased AU2016210988B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562108222P 2015-01-27 2015-01-27
US62/108,222 2015-01-27
GB1501302.2 2015-01-27
GBGB1501302.2A GB201501302D0 (en) 2015-01-27 2015-01-27 Embryo implantation
PCT/GB2016/050175 WO2016120617A1 (en) 2015-01-27 2016-01-27 Embryo implantation

Publications (2)

Publication Number Publication Date
AU2016210988A1 AU2016210988A1 (en) 2017-08-17
AU2016210988B2 true AU2016210988B2 (en) 2021-04-29

Family

ID=52673965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016210988A Ceased AU2016210988B2 (en) 2015-01-27 2016-01-27 Embryo implantation

Country Status (13)

Country Link
US (2) US10293029B2 (enExample)
EP (1) EP3250224B1 (enExample)
JP (1) JP6826983B2 (enExample)
CN (1) CN107206054B (enExample)
AU (1) AU2016210988B2 (enExample)
CA (1) CA2973793A1 (enExample)
DK (1) DK3250224T3 (enExample)
ES (1) ES2790743T3 (enExample)
GB (2) GB201501302D0 (enExample)
PL (1) PL3250224T3 (enExample)
PT (1) PT3250224T (enExample)
SG (1) SG11201705851RA (enExample)
WO (1) WO2016120617A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CN113584180B (zh) * 2021-07-06 2024-02-06 浙江大学 子宫内膜来源的外分泌体miRNA在胚胎着床中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563846B2 (enExample) 1972-10-12 1981-01-27
US4211769A (en) 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
AUPO550897A0 (en) 1997-03-06 1997-03-27 Luminis Pty Limited Treatment and diagnosis of an infertility condition
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
CA2373073A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
AU2002951531A0 (en) 2002-09-20 2002-10-03 The University Of Adelaide Treatment and diagnosis of an infertility condition by measuring or inhibiting interferon-y
KR20050094832A (ko) 2002-12-31 2005-09-28 알투스 파마슈티컬스 인코포레이티드 단백질 결정과 이온성 중합체를 함유하는 복합체
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CN101123977A (zh) * 2003-03-25 2008-02-13 海里康公司 用于诱导治疗应答的组合物
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
CA2540838C (en) 2003-10-03 2014-12-16 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US8338373B2 (en) 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
WO2005115456A2 (en) 2004-05-28 2005-12-08 President And Fellows Of Harvard College METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY
EP2465534B1 (en) 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
WO2007113682A2 (en) 2006-04-06 2007-10-11 Novozymes Gropep Ltd Tgf-beta pharmaceutical compositions
AU2007325465B2 (en) 2006-11-28 2013-09-05 Pictor Limited Assay membrane and method of use thereof
PT2101760E (pt) 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
WO2008070902A1 (en) 2006-12-11 2008-06-19 Novozymes Biopharma Au Limited Tgf-beta compositions for treating infertility
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
EP2183254B1 (en) 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
US8003324B2 (en) 2007-10-18 2011-08-23 U.S. Department Of Veterans Affairs Modulation of sodium channels by nicotinamide adenine dinucleotide
GB0806281D0 (en) 2008-04-07 2008-05-14 Univ Leeds Markers of Oocyte viability
WO2009139784A1 (en) 2008-05-13 2009-11-19 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010126528A1 (en) 2009-05-01 2010-11-04 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2443230B1 (en) 2009-06-18 2017-07-26 Takara Bio Europe AB 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
AU2011256088B2 (en) 2010-05-20 2015-03-26 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US8518879B2 (en) * 2011-03-04 2013-08-27 Ahmed H. Al-Qahtani Skin cream
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
ITMI20122063A1 (it) 2012-12-03 2014-06-04 Marco Sbracia Gm-csf per l'utilizzo nella prevenzione dell'aborto spontaneo e del fallimento dell'impianto dell'embrione
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
WO2015081157A1 (en) 2013-11-27 2015-06-04 Jbs United Animal Health Ii Llc Method and composition for synchronizing time of insemination in gilts
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JE SCHJENKEN ET AL, "Seminal Fluid and Immune Adaptation for Pregnancy - Comparative Biology in Mammalian Species", REPRODUCTION IN DOMESTIC ANIMALS, DE, (2014-09-15), vol. 49, doi:10.1111/rda.12383, ISSN 0936-6768, pages 27- 36 *

Also Published As

Publication number Publication date
US10987406B2 (en) 2021-04-27
WO2016120617A1 (en) 2016-08-04
US20160213749A1 (en) 2016-07-28
US10293029B2 (en) 2019-05-21
JP6826983B2 (ja) 2021-02-10
GB201501302D0 (en) 2015-03-11
GB2539986B (en) 2017-07-12
JP2018507189A (ja) 2018-03-15
CN107206054A (zh) 2017-09-26
PT3250224T (pt) 2020-05-18
CA2973793A1 (en) 2016-08-04
US20190216896A1 (en) 2019-07-18
GB201601505D0 (en) 2016-03-09
ES2790743T3 (es) 2020-10-29
CN107206054B (zh) 2021-08-20
DK3250224T3 (da) 2020-05-18
SG11201705851RA (en) 2017-08-30
PL3250224T3 (pl) 2020-07-13
GB2539986A (en) 2017-01-04
EP3250224B1 (en) 2020-04-22
AU2016210988A1 (en) 2017-08-17
EP3250224A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
Brown et al. Natural versus chorionic gonadotropin-induced ovarian responses in the clouded leopard (Neofelis nebulosa) assessed by fecal steroid analysis
US10588944B2 (en) Methods and compositions for managing reproduction
AU2014307714B2 (en) Embryo implantation
US10987406B2 (en) Embryo implantation
Odhiambo et al. Pregnancy outcome in dairy and beef cattle after artificial insemination and treatment with seminal plasma or transforming growth factor beta-1
Cambra et al. Allogeneic embryos disregulate leukemia inhibitory factor (LIF) and its receptor in the porcine endometrium during implantation
WO1997007813A1 (en) Fertility agent
CN101287826A (zh) 培养胚胎和卵母细胞的组合物和方法
US20240358799A1 (en) Methods and compositions for reproductive management of sheep and goats
Esparza-Harris Interaction of number of boar sperm and insemination timing on fertility following induced ovulation
JPWO1997007813A1 (ja) 受胎促進剤
Wang et al. Advances in interspecific pregnancy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired